Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antihypercholesterolemic activity of RN-316 confirmed in early clinical studies

Nov. 7, 2012

Phase III study of BMN-110 meets primary endpoint

Nov. 7, 2012

European authorities accept Ferring's MAA for MVDS in induction of labor

Nov. 6, 2012

Glybera gene therapy approved by the European Commission

Nov. 5, 2012

Degarelix evaluated in women undergoing in vitro fertilization

Nov. 5, 2012

European Commission denies marketing authorization for taliglucerase alfa

Nov. 5, 2012

Encouraging phase III results presented for Biocon's insulin biosimilar

Nov. 5, 2012

Novo Nordisk completes phase I trial of oral GLP-1 analogue

Nov. 2, 2012

Phenex's PX-102 proves safe and well tolerated in phase I study

Nov. 2, 2012

Novel cannabinoid CB1 receptor antagonists synthesized by Korean group

Nov. 2, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...